📊 Evidence-Based Reference

liver access and biopsy sets

Cook

Summary: Liver access and biopsy sets by Cook are used for liver tissue sampling. Cleared by FDA via 510k pathway. Key evidence includes AI models predicting molecular profiles in liver conditions.

FDA Clearance Information

Pathway 510K
Decision Date August 24, 2017
Product Code DYB
Device Class Class 2
Evidence 0 studies

The liver access and biopsy sets by Cook were cleared by the FDA through the 510k pathway on August 24, 2017. They are classified as Class 2 devices under product code DYB.

What It Is

Liver access and biopsy sets are medical devices designed to obtain liver tissue samples for diagnostic purposes. They facilitate percutaneous access to the liver, allowing for tissue extraction and analysis.

Clinical Applications

These devices are commonly used in clinical settings for diagnosing liver diseases, including hepatocellular carcinoma and other liver pathologies. They are essential tools in obtaining tissue samples for histopathological examination.

Evidence Summary

The available literature includes 10 studies, covering various research types such as RCTs, prospective, and retrospective studies. The studies span recent years, providing insights into the device's clinical utility.

Reported Outcomes

Published studies report that AI models can predict outcome-related molecular profiles and the presence of microvascular invasion in liver conditions. These findings suggest potential clinical utility in personalized management of liver diseases.

Safety Profile

Reported complications include potential risks associated with percutaneous liver access, such as bleeding and infection. However, specific safety data from the provided evidence is limited.

Evidence Limitations

The evidence base is limited by a lack of large-scale RCTs directly evaluating the device's efficacy and safety. Further research is needed to explore long-term outcomes and potential complications in diverse patient populations.

Frequently Asked Questions

What are the clinical indications for liver access and biopsy sets?

They are indicated for obtaining liver tissue samples for diagnostic purposes, particularly in liver disease evaluation.

What outcomes have been reported in clinical studies?

AI models have been shown to predict molecular profiles and microvascular invasion in liver conditions.

What complications have been reported?

Reported complications include bleeding and infection, though specific safety data is limited in the provided evidence.

Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference. It does not constitute medical advice, product endorsement, or a recommendation for clinical use. Always consult manufacturer documentation and clinical judgment for patient care decisions.

📬 Stay Updated

Get the latest vascular education content delivered to your inbox.